Notably, only one biological agent has received approval for use in both diseases: the anti‐IL4/IL13 dupilumab is effective at reducing exacerbation rates [11] and maintenance oral corticosteroid (mOCS) use [12] in severe asthma, and it also significantly reduces disease burden in atopic dermatitis [13]. The gene discussed is IL13; the disease is asthma.